Optometry; TPA-Formulary; TPA-Formulary Committee; dissolution.
HB1898 revises Virginia’s optometry statutes governing therapeutic pharmaceutical agents (TPAs) and the TPA-Formulary. It continues to authorize TPA-certified optometrists to prescribe and administer certain controlled substances and drugs for diseases and abnormal conditions of the eye and its adnexa, including hydrocodone-acetaminophen, selected oral analgesics, topical Schedule VI drugs, and intramuscular epinephrine for emergency anaphylaxis. The bill also preserves limits on optometric practice by prohibiting surgery and most invasive procedures, restricting injection authority to chalazion treatment with required training, and barring treatment of infantile or congenital glaucoma.
A central feature of the bill is the restructuring of how the TPA-Formulary is maintained. It directs the Board of Optometry to regulate and update the formulary, treatment guidelines, and treatable conditions, while requiring public notice and a hearing before amendments take effect. It also establishes a seven-member TPA-Formulary Committee made up of optometrists, a pharmacist, ophthalmologists, and a chair appointed by the Board of Optometry to recommend drugs for inclusion on the formulary. The bill further clarifies that pharmacies, wholesalers, and other authorized distributors may supply the drugs specified by the Board.
The bill’s impact on state law is to update and consolidate the statutory framework for optometric prescribing authority and the administration of TPAs under the Drug Control Act. It amends related prescription and exceptions provisions so that TPA-certified optometrists are explicitly recognized as prescribers of the limited formulary drugs and may provide samples or prescriptions within their scope of practice. It also preserves existing controlled-substance safeguards, bona fide practitioner-patient relationship requirements, and pharmacist verification duties, while aligning optometry-specific rules with broader prescribing and dispensing laws.
The overall sentiment reflected in the voting history is strongly supportive and noncontroversial. The bill advanced unanimously through subcommittee, full committee, and both chambers, with no recorded dissenting votes. That pattern suggests broad agreement that the measure is a technical or regulatory update to optometry practice rather than a major policy dispute.
There is little visible contention in the available record, but the bill’s structure indicates the main policy sensitivities are around patient safety, scope of practice, and oversight of the formulary. The statutory limits on injections, emergency care, and prohibited procedures, along with the requirement for public hearings and committee input, appear designed to address concerns from medical and pharmacy stakeholders about maintaining appropriate clinical standards while allowing optometrists limited prescribing authority.
HB1898 amends Virginia Code sections 54.1-3222, 54.1-3223, 54.1-3301, and 54.1-3303 to update the legal framework for TPA-certified optometrists. It preserves and clarifies the limited set of drugs and controlled substances optometrists may prescribe or administer, formalizes the TPA-Formulary process, and establishes a TPA-Formulary Committee to recommend formulary changes. It also integrates optometry into the state’s controlled-substance and prescription rules while maintaining restrictions on invasive procedures and requiring public notice and hearing procedures for formulary amendments.
The bill appears to have been received positively and without meaningful opposition. It moved through subcommittee, committee, and floor votes unanimously in both the House and Senate, indicating broad bipartisan or cross-chamber support. The available record suggests the measure was viewed as a routine professional-practice update rather than a controversial expansion of authority.
No specific objections are recorded in the provided materials, and the unanimous votes indicate no active floor-level controversy. The likely areas of concern, based on the bill text, are the scope of optometrists’ prescribing authority, the inclusion of controlled substances, and the balance between professional autonomy and patient safety. Those concerns are addressed in the bill through narrow drug limits, training requirements for injections, prohibitions on surgery and certain glaucoma treatment, and continued oversight by the Board of Optometry with input from pharmacy and ophthalmology representatives.